戻る Agenda
Session 8: Will Artificial Intelligence (AI) Transform Drug Labeling Processes?
Session Chair(s)
Deborah Bebbington
Head Global Labeling
Bayer Plc, United Kingdom
Mary Beth Wilusz
Head, Regulatory Labeling Operations and Compliance
Daiichi Sankyo, Inc., United States
This session will examine the transformative role of artificial intelligence (AI), neuro linguistic programming (NLP), and machine learning (ML) in global regulatory labeling, highlighting opportunities to enhance efficiency, accuracy, and compliance. Speakers will discuss how these technologies can streamline processes, from automating label updates to analyzing health authority requirements, while addressing challenges such as integration and data privacy. Attendees will gain insights into how AI-driven innovations are reshaping labeling processes, future directions in the industry, and strategies for collaborating with health authorities to navigate the evolving regulatory landscape.
Learning Objective : - Describe how to structure prompts to generate appropriate AI output
- Identify specific areas of the labeling process that can benefit from the use AI, NLP or ML
- Evaluate the future role and potential of AI in the regulatory labeling landscape
Speaker(s)
Speaker
Irene Kuhlman, MSc
Bayer Pharma NL, Netherlands
Global Labeling Strategist
Speaker
Mike DeMarco, PharmD
PwC, United States
Director, Clinical Transformation R&D Managment Consulting
Speaker
Michelle Wu, MBA
NyquistAI, United States
Co-founder & CEO